Pharmacogenomics in dermatology

From susceptibility genes to personalized therapy

Carlo Pincelli, Marco Pignatti, Riccardo G. Borroni

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A significant proportion of patients with skin disease do not respond to treatment and adverse drug reactions are a common problem. Genetic factors are important determinants for both drug efficacy and toxicity. The fields of pharmacogenetics and pharmacogenomics examine inter- individual variations in the DNA sequence that are related to drug efficacy and toxicity. Here, we present pharmacogenomic data relevant to dermatology and explore the role of dermatologists in identifying patients who may respond to treatment or experience adverse drug reactions.

Original languageEnglish
Pages (from-to)337-349
Number of pages13
JournalExperimental Dermatology
Volume18
Issue number4
DOIs
Publication statusPublished - 2009

Fingerprint

Dermatology
Pharmacogenetics
Drug-Related Side Effects and Adverse Reactions
Genes
Pharmaceutical Preparations
Toxicity
DNA sequences
Therapeutics
Skin Diseases
Skin

Keywords

  • Adverse drug reactions
  • Atopic dermatitis
  • Melanoma
  • Pharmacogenetics
  • Pharmacogenomics
  • Psoriasis

ASJC Scopus subject areas

  • Dermatology
  • Molecular Biology
  • Biochemistry

Cite this

Pharmacogenomics in dermatology : From susceptibility genes to personalized therapy. / Pincelli, Carlo; Pignatti, Marco; Borroni, Riccardo G.

In: Experimental Dermatology, Vol. 18, No. 4, 2009, p. 337-349.

Research output: Contribution to journalArticle

@article{dc26f76d8f6a44b7af538f31c6a5428f,
title = "Pharmacogenomics in dermatology: From susceptibility genes to personalized therapy",
abstract = "A significant proportion of patients with skin disease do not respond to treatment and adverse drug reactions are a common problem. Genetic factors are important determinants for both drug efficacy and toxicity. The fields of pharmacogenetics and pharmacogenomics examine inter- individual variations in the DNA sequence that are related to drug efficacy and toxicity. Here, we present pharmacogenomic data relevant to dermatology and explore the role of dermatologists in identifying patients who may respond to treatment or experience adverse drug reactions.",
keywords = "Adverse drug reactions, Atopic dermatitis, Melanoma, Pharmacogenetics, Pharmacogenomics, Psoriasis",
author = "Carlo Pincelli and Marco Pignatti and Borroni, {Riccardo G.}",
year = "2009",
doi = "10.1111/j.1600-0625.2009.00852.x",
language = "English",
volume = "18",
pages = "337--349",
journal = "Experimental Dermatology",
issn = "0906-6705",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Pharmacogenomics in dermatology

T2 - From susceptibility genes to personalized therapy

AU - Pincelli, Carlo

AU - Pignatti, Marco

AU - Borroni, Riccardo G.

PY - 2009

Y1 - 2009

N2 - A significant proportion of patients with skin disease do not respond to treatment and adverse drug reactions are a common problem. Genetic factors are important determinants for both drug efficacy and toxicity. The fields of pharmacogenetics and pharmacogenomics examine inter- individual variations in the DNA sequence that are related to drug efficacy and toxicity. Here, we present pharmacogenomic data relevant to dermatology and explore the role of dermatologists in identifying patients who may respond to treatment or experience adverse drug reactions.

AB - A significant proportion of patients with skin disease do not respond to treatment and adverse drug reactions are a common problem. Genetic factors are important determinants for both drug efficacy and toxicity. The fields of pharmacogenetics and pharmacogenomics examine inter- individual variations in the DNA sequence that are related to drug efficacy and toxicity. Here, we present pharmacogenomic data relevant to dermatology and explore the role of dermatologists in identifying patients who may respond to treatment or experience adverse drug reactions.

KW - Adverse drug reactions

KW - Atopic dermatitis

KW - Melanoma

KW - Pharmacogenetics

KW - Pharmacogenomics

KW - Psoriasis

UR - http://www.scopus.com/inward/record.url?scp=63149128048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63149128048&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0625.2009.00852.x

DO - 10.1111/j.1600-0625.2009.00852.x

M3 - Article

VL - 18

SP - 337

EP - 349

JO - Experimental Dermatology

JF - Experimental Dermatology

SN - 0906-6705

IS - 4

ER -